Abstract: The present invention relates to oral dosage forms comprising letermovir and, in particular, to compressed mini-tablets comprising letermovir. The invention also relates to methods of using the oral dosage forms for the treatment, prevention, or prophylaxis of HCMV in a patient. In addition, the invention also provides methods for making the mini-tablets of the invention.

Abstract: The invention relates to stable formulations of cyclic dinucleotide STING agonist compounds or pharmaceutically acceptable salts thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intratumoral or subcutaneous administration.

Abstract: Systems, methods, and apparatuses for maintaining and processing proprietary or sensitive data using an application implemented in a split/hybrid-cloud system are described. The split/hybrid system utilizes cloud and local platforms, while complying with customer security concerns and HIPAA security standards. Configuration of the application occurs in a cloud platform whereas processing of proprietary or sensitive data occurs within a customer's local computing environment. The customer may create their own unique application configuration that is stored in the cloud platform and that is delivered back to the customer as a package that includes both the unique application configuration as well as general application configuration requirements. The customer may implement the package within one or more local computing environments while managing the application from a single site that is separated from proprietary or sensitive data.

Abstract: Systems, methods, and apparatuses for maintaining and processing proprietary or sensitive data using an application implemented in a split/hybrid-cloud system are described. The split/hybrid system utilizes cloud and local platforms, while complying with customer security concerns and HIPAA security standards. Configuration of the application occurs in a cloud platform whereas processing of proprietary or sensitive data occurs within a customer's local computing environment. The customer may create their own unique application configuration that is stored in the cloud platform and that is delivered back to the customer as a package that includes both the unique application configuration as well as general application configuration requirements. The customer may implement the package within one or more local computing environments while managing the application from a single site that is separated from proprietary or sensitive data.

Abstract: 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one (Compound I) has surprisingly improved solubility, bioavailability and stability in an ampiphilic vehicle that can include propylene glycol, a propylene glycol sparing agent, an antioxidant, or a mixture thereof. In one embodiment of the present invention is a solution comprising the active or a pharmaceutically acceptable salt or solvate thereof, and an amphiphilic agent, said amphiphilic agent being a fatty acid ester of glycerol, propylene glycol or sorbitol.